Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Many people who immediately change into comfy clothes when they get home possess several personality traits that help them embrace the positive outcomes of choosing comfier clothing options. These ...
While the Earth has gone through some dramatic climate changes in its 4.6-billion-year history, natural processes like silicate weathering can help return things to a comfortable equilibrium. A new ...
An announcement from Vertex Minerals Ltd. ( (AU:VTX)) is now available. Vertex Minerals Limited has announced a change in its auditing firm, with the Australian Securities and Investments Commission ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
MSNBC will start going by MS NOW later this month. Starting Nov. 15, the liberal cable news network will be called “My Source for News, Opinion, and the World” or MS NOW for short. It will also drop ...
Vertex Pharmaceuticals Incorporated remains a leader in cystic fibrosis treatments, fueling robust cash flow and funding a promising pipeline expansion. VRTX is seeing early but accelerating revenue ...
Edward White does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...
Performances in N.Y.C. Broadway plans to replace the cast-change slips that are stuffed into Playbills with QR codes. Some understudies and theater buffs will mourn their loss. Broadway plans to ...
Plan on a glorious extra hour of sleep as most of America “falls back” into standard time. But make sure to get outside for some morning sun, too — it’ll help your body clock reset faster. Daylight ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...